Ilya Pharma, an innovative Swedish pharmaceutical company, develops drug candidates for Proof of Concept in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins. Ilya Pharma was granted € 3M from the SME Instrument HORIZON 2020, phase 2.
“The cooperation with GAEU has been very successful with Ilya Pharma. GAEU’s consultants handled the process excellently. They possess eminent knowledge on how to break down a very complex project into smaller, logical activities, and on how the different parts are connected. It feels very good to have GAEU standing beside us in the process when we are to deliver this 18 months project”
Evenlina Vågesjö, CEO, Ilya Pharma